Fragile X Research and Treatment Program
Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and the most common known single-gene mutation leading to autism. The clinical features of FXS range from mild emotional, sensory and/or learning problems to severe intellectual disabilities and autism. The MIND Institute established the Fragile X Research and Treatment Program directed by Randi Hagerman, M.D., in 2001. Our clinical evaluations and treatments of patients with fragile X is an important component of our center and our clinical experience guides our research.
Our center utilizes the expertise of professionals in various clinical disciplines, including Drs. Leonard Abbeduto, David Hessl, Susan Rivera and Andrea Schneider, and molecular genetics, including Drs. Paul Hagerman and Flora Tassone. The close interaction of clinicians and scientists has led to important advances in our understanding of fragile X-related conditions and treatment.
An interdisciplinary staff and faculty are involved with the Fragile X Research and Treatment Program, including specialists in pediatrics, molecular genetics, psychiatry, psychology, neurology, neurobiology, pathology and social work.
Most families who participate in an evaluation are involved with both clinical work and research protocols. We have evaluated children and adults with fragile X syndrome and also carriers with the premutation from locations regionally, nationally and internationally.
Current Research Studies
We provide comprehensive clinical services, including psychological testing and medical assessment.
Massie Family Clinic